Literature DB >> 1392742

Adjuvant treatment for breast cancer: the overview.

R D Gelber, A S Coates, A Goldhirsch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392742      PMCID: PMC1882838          DOI: 10.1136/bmj.304.6831.859

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  4 in total

1.  Can a clinical trial be the treatment of choice for patients with cancer?

Authors:  R D Gelber; A Goldhirsch
Journal:  J Natl Cancer Inst       Date:  1988-08-17       Impact factor: 13.506

2.  Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.

Authors:  R D Gelber; A Goldhirsch; F Cavalli
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

3.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.

Authors:  A Goldhirsch; R D Gelber; R J Simes; P Glasziou; A S Coates
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

4.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.

Authors:  M L Slevin; L Stubbs; H J Plant; P Wilson; W M Gregory; P J Armes; S M Downer
Journal:  BMJ       Date:  1990-06-02
  4 in total
  1 in total

Review 1.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.